MiMedx Group (MDXG) Stock Price, News & Analysis

Company Overview

MiMedx Group, Inc. is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair. The company also supplies specialized bioimplants for orthopedic and spine procedures, supporting soft-tissue repair through its PURION® Plus technology platform. These products are used by wound care centers, hospitals, long-term care facilities and physician offices.

Headquartered in Marietta, Georgia, MiMedx serves a primarily U.S. customer base, with a growing international presence through distributors and strategic partnerships in Europe, Asia and Latin America. The company’s direct sales force works alongside a network of third-party distributors to educate clinicians on the clinical and economic benefits of its regenerative therapies. MiMedx continues to invest in clinical research and educational programs to expand awareness of placental-derived tissue allografts across multiple therapeutic areas.

Founded in 2008, MiMedx has grown from a niche tissue processor to an established player in the regenerative medicine sector. Over its history, the company has received approvals from the U.S. Food and Drug Administration for tissue donor eligibility and manufacturing practices governed by FDA and American Association of Tissue Banks (AATB) standards. Leadership includes experienced professionals in biotechnology and medical device commercialization, supported by a board with backgrounds in healthcare investment and corporate governance.

Key Stats

• Today's Range: $6.91 to $7.08
• 50-Day Range: $6.33 to $7.31
• 52-Week Range: $5.47 to $10.14
• Volume: 833,337 shs
• Average Volume: 411,550 shs
• Market Capitalization: $1.03 billion
• P/E Ratio: 33.19
• Dividend Yield: N/A
• Price Target: $12.00
• Consensus Rating: Buy

MiMedx Group Stock Analysis - MarketRank™

MiMedx Group scored higher than 70% of companies evaluated by MarketBeat, and ranked 319th out of 958 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.7 / 5
• Analyst Rating: Buy

Consensus Rating

MiMedx Group has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.

Upside Potential

MiMedx Group has a consensus price target of $12.00, representing about 72.2% upside from its current price of $6.97.

Amount of Analyst Coverage

MiMedx Group has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 1.9 / 5
• Proj. Earnings Growth: 6.67%

Earnings Growth

Earnings for MiMedx Group are expected to grow by 6.67% in the coming year, from $0.30 to $0.32 per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of MiMedx Group is 33.19, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 280.66.

Price to Earnings Ratio vs. Sector

The P/E ratio of MiMedx Group is 33.19, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 75.86.

Price to Book Value per Share Ratio

MiMedx Group has a P/B Ratio of 5.32. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 3.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

3.42% of the float of MiMedx Group has been sold short.

Short Interest Ratio / Days to Cover

MiMedx Group has a short interest ratio ("days to cover") of 6.8.

Change versus previous month

Short interest in MiMedx Group has recently decreased by 0.80%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

MiMedx Group does not currently pay a dividend.

Dividend Growth

MiMedx Group does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

3.42% of the float of MiMedx Group has been sold short.

Short Interest Ratio / Days to Cover

MiMedx Group has a short interest ratio ("days to cover") of 6.8.

Change versus previous month

Short interest in MiMedx Group has recently decreased by 0.80%, indicating that investor sentiment is improving.

News and Social Media

• Score: 3.3 / 5
• News Sentiment: N/A

News Sentiment

MiMedx Group has a news sentiment score of 1.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.92 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for MiMedx Group this week, compared to 4 articles on an average week.

MarketBeat Follows

8 people have added MiMedx Group to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 1.7 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, MiMedx Group insiders have not sold or bought any company stock.

Percentage Held by Insiders

Only 1.70% of the stock of MiMedx Group is held by insiders.

Percentage Held by Institutions

79.15% of the stock of MiMedx Group is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

MDXG Stock Analysis - Frequently Asked Questions

How have MDXG shares performed this year?

MiMedx Group's stock was trading at $9.62 at the beginning of the year. Since then, MDXG stock has decreased by 27.5% and is now trading at $6.97.

How were MiMedx Group's earnings last quarter?

MiMedx Group, Inc (NASDAQ:MDXG) announced its quarterly earnings data on Wednesday, July, 30th. The company reported $0.10 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.06 by $0.04. The company earned $98.61 million during the quarter, compared to the consensus estimate of $90.79 million. MiMedx Group had a trailing twelve-month return on equity of 23.03% and a net margin of 8.84%.
Read the conference call transcript.

Who are MiMedx Group's major shareholders?

Top institutional shareholders of MiMedx Group include Trigran Investments Inc. (5.67%), Paradigm Capital Management Inc. NY (3.01%), Geode Capital Management LLC (1.92%) and Cannell Capital LLC (1.40%). Insiders that own company stock include Joseph H Capper, William Frank Iv Hulse, Ricci S Whitlow, Robert Benjamin Stein, Kimberly Maersk-Moller, William Lawrence Phelan and Rice Doug.
View institutional ownership trends.

How do I buy shares of MiMedx Group?

Shares of MDXG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of MiMedx Group own?

Based on aggregate information from My MarketBeat watchlists, some other companies that MiMedx Group investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Hawkins (HWKN), Adobe (ADBE) and GE Aerospace (GE).

Company Calendar

• Last Earnings: 7/30/2025
• Today: 9/16/2025
• Next Earnings (Estimated): 10/29/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Medical Equipment
• Current Symbol: NASDAQ:MDXG
• CIK: 1376339
• Web: www.mimedx.com
• Phone: (770) 651-9100
• Fax: 678-384-6741
• Employees: 870
• Year Founded: N/A

Price Target and Rating

• Average Price Target for MiMedx Group: $12.00
• High Price Target: $12.00
• Low Price Target: $12.00
• Potential Upside/Downside: +72.2%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 1 Analysts

Profitability

• EPS (Trailing Twelve Months): $0.21
• Trailing P/E Ratio: 23.23
• Forward P/E Ratio: 23.23
• P/E Growth: N/A
• Net Income: $42.42 million
• Net Margins: 8.84%
• Pretax Margin: 12.18%
• Return on Equity: 23.03%
• Return on Assets: 17.09%

Debt

• Debt-to-Equity Ratio: 0.08
• Current Ratio: 4.39
• Quick Ratio: 3.90

Sales & Book Value

• Annual Sales: $348.88 million
• Price / Sales: 2.96
• Cash Flow: $0.33 per share
• Price / Cash Flow: 21.04
• Book Value: $1.31 per share
• Price / Book: 5.32

Miscellaneous

• Outstanding Shares: 147,960,000
• Free Float: 145,444,000
• Market Cap: $1.03 billion
• Optionable: Optionable
• Beta: 1.74